as 3201 has been researched along with epalrestat in 3 studies
| Studies (as 3201) | Trials (as 3201) | Recent Studies (post-2010) (as 3201) | Studies (epalrestat) | Trials (epalrestat) | Recent Studies (post-2010) (epalrestat) |
|---|---|---|---|---|---|
| 33 | 7 | 12 | 243 | 22 | 100 |
| Protein | Taxonomy | as 3201 (IC50) | epalrestat (IC50) |
|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | 7.9635 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 6.5 | |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 0.1836 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.5596 | |
| Aldo-keto reductase family 1 member A1 | Homo sapiens (human) | 2.6 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 0.1335 | |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | 0.17 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.085 | |
| Aldo-keto reductase family 1 member A1 | Sus scrofa (pig) | 1.5 | |
| Aldo-keto reductase family 1 member A1 | Rattus norvegicus (Norway rat) | 1.5 | |
| Aldo-keto reductase family 1 member B7 | Rattus norvegicus (Norway rat) | 1.198 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hotta, N | 1 |
| Kakehashi, A; Kinoshita, N; Matsumoto, T; Ota, A; Shimmura, M; Takano, H; Tanaka, Y; Toyoda, F; Tsuji, J | 1 |
| Ishibashi, Y; Kato, H; Matsui, T; Matsumoto, T; Yamagishi, S | 1 |
1 review(s) available for as 3201 and epalrestat
| Article | Year |
|---|---|
[Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor].
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetic Angiopathies; Drug Design; Humans; Imidazolidines; Polymers; Polymorphism, Genetic; Pyrazines; Rhodanine; Spiro Compounds; Thiazolidines | 2005 |
2 other study(ies) available for as 3201 and epalrestat
| Article | Year |
|---|---|
Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Retinopathy; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glycated Hemoglobin; Male; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Retina; Rhodanine; Spiro Compounds; Thiazolidines; Time Factors | 2014 |
Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Topics: Aldehyde Reductase; Anti-Inflammatory Agents; Cell Line, Tumor; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Inflammation Mediators; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rhodanine; Sorbitol; Spiro Compounds; Superoxides; Tandem Mass Spectrometry; Thiazolidines; Vascular Cell Adhesion Molecule-1 | 2016 |